Donald R Shaffer

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 10

Top Topics

Regulatory T Cells

Immune Response

Top Venues

The Journal of experimental medicine

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Benjamin Umiker, Yasmin Hashambhoy-Ramsay, Jeff Smith, Tanzila Rahman, Amy Mueller, Rachel Davidson, Christina Meyer, Gayatri Patankar, Mohammad Murshid Alam, Sarah Jaffe, Kristin Krukenberg, Allison Goodman, Vikki Spaulding, Michelle Priess, Abha Dhaneshwar, Masie Wong, Alexa Diiorio, Kristin O'Malley, Lara McGrath, Margaret Willer, Lauren Pepper, Monica Gostissa, Katalin Kis-Toth, Dmitri Wiederschain, Heather Cohen, Donald R Shaffer
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T Cell Activation in Tumors. Molecular cancer therapeutics (2023)